Human immunodeficiency virus type 1 (HIV-1)-specific cytotoxic T lymphocytes (CTLs) play a key role in suppression of HIV-1 replication [1] [2] [3] [4] [5] [6] [7] [8] . Particular HLA-B alleles, such as HLA-B*57 and HLA-B*27, have the greatest impact on the control of HIV-1 replication by HIV-1-specific T cells [9] [10] [11] [12] , whereas there have been only a few studies on the suppression of HIV-1 replication by HIV-1-specific HLA-C-restricted CTLs. Previous studies showed that HLA-C*03, HLA-C*07-, HLA-C*12-, or HLA-C*15-restricted HIV-1-specific CTLs recognize HIV-1-infected cells and have the ability to suppress HIV-1 replication in vitro [13, 14] . A subsequent study demonstrated that HLA-C expression level is negatively associated with plasma viral load (pVL) in Europeans and African Americans and positively so with HLA-C-restricted CTL responses in Africans [15] . These findings together suggested that HLA-C-restricted CTLs may play an important role in control of HIV-1, although they has not yet been directly demonstrated.
HLA-B*57, HLA-B*58, and HLA-B*27 are well-known protective alleles for AIDS progression in Caucasians infected with HIV-1 subtype B and in Africans with subtype C, respectively [5, [16] [17] [18] [19] [20] [21] , whereas HLA-B*52:01-C*12:02 haplotype and HLA-B*67:01 allele are protective in Japanese individuals who do not have HLA-B*57, HLA-B*58, or HLA-B*27 at appreciable frequencies [22] . HLA-B*52:01 is also reported as one of the protective alleles in Europeans [23] . Later studies demonstrated that HLA-B*52:01-restricted and HLA-B*67:01-restricted CD8 + T cells have stronger abilities to control HIV-1 in the Japanese population [24] and that the total number of escape mutations selected by HLA-B*52:01 is associated with a lower pVL in HLA-B*52:01 + individuals [25] , suggesting a reduction in virus fitness in HIV-1 escape mutants selected by HLA-B*52:01-restricted CTLs.
These findings strongly suggested that HLA-B*52:01-restricted T-cell-mediated immune responses contribute to the control of HIV-1 replication in Japanese individuals. On the other hand, a 2016 study on natural killer (NK) cells demonstrated that individuals carrying both HLA-C*12:02 and KIR2LD2 have a lower pVL than those carrying either one or neither [26] . Because HLA-C*12:02, in the HLA-C1 group, is a ligand for KIR2LD2, the study findings suggested that HLA-C*12:02-restricted NK cell-mediated immune pressure may contribute to the control of HIV-1 in some HLA-C*12:02 + individuals. The HLA-B*52:01-C*12:02 haplotype, the most prevalent haplotype in Japanese individuals (seen in approximately 20%), has strong linkage disequilibrium (relative linkage disequilibrium value, 0.99) [27, 28] , so it is difficult to discriminate between the impact of HLA-C*12:02-and HLA-B*52:01-restricted T-cell-mediated immune pressure on clinical outcomes. In other populations, such as those in China, India, Turkey, and Israel, HLA-B*52:01 and HLA-C*12:02 are not in linkage disequilibrium [29, 30] . However, there are no genetic/ epidemiological reports of the effects of these HLA alleles on HIV-1 infection in these populations. Thus, it still remains unclear whether HLA-C*12:02-restricted T-cell-mediated immune pressure contributes to the control of HIV-1.
In this present study, we sought to clarify the role of HLA-C*12:02-restricted CTLs in the control of HIV-1 in Japanese individuals. Because only 2 HLA-C*12:02 epitopes are known [31] , we first identified novel HLA-C*12:02-restricted HIV-1 epitopes and then characterized the responses of CD8 + T cells specific for these epitopes. We finally evaluated the impact of HLA-C*12:02-restricted CTLs on the clinical outcome and, further, that on that of both HLA-C*12:02-and HLA-B*52:01-restricted CTLs.
METHODS

Subjects
All treatment-naive Japanese individuals chronically infected with HIV-1 subtype B were recruited from the National Center for Global Health and Medicine. This study was approved by the ethics committees of Kumamoto University and the National Center for Global Health and Medicine. Informed consent was obtained from all individuals according to the Declaration of Helsinki. Plasma and peripheral blood mononuclear cells (PBMCs) were separated from whole blood. HLA types of the individuals were determined by means of standard sequencebased genotyping.
Peptides
Peptides (8-11-mer) and peptide cocktails (11 and 17 mer) were synthesized using an automated multiple peptide synthesizer and purified using high-performance liquid chromatography. Their purity (>90%) was examined with high-performance liquid chromatography and mass spectrometry. The peptides used in the present study were shown in Supplementary Table S1 .
Cell Lines
C1R cells expressing HLA-C*12:02 (C1R-C1202) and 721.221 cells expressing CD4 molecules and HLA-B*52:01 (.221-B5201) or HLA-C*12:02 (.221-C1202) were previously generated [14, 32] . A transporter associated with antigen processing 2 (TAP2)-defective mouse cell line RMA-S expressing HLA-C*12:02 (RMA-S-C1202) was constructed earlier [33] . These cell lines were cultured in Roswell Park Memorial Institute 1640 medium containing 10% FCS medium (R10) with 0.15 mg/mL hygromycin B. Epstein-Barr virus-transformed B-lymphoblastoid cell lines (B-LCLs) were established by transforming B cells from PBMCs of laboratory volunteers and HIV-1-infected individuals. The PBMCs were plated at 3 × 10 6 cells per well in flat-bottomed 24-well plates in R10 medium supplemented with 2 mg/ mL cyclosporin A and the supernatant derived from the cultures of B95-8 cell line producing Epstein-Barr virus [34] .
Epitope-Specific CTL Clones
The Nef MY9 epitope-specific CTL clones established from Nef MY9-specific bulk T cells were derived from a chronically HIV-1-infected individual KI-069. Briefly, Nef MY9-specific bulk T cells were obtained by stimulating PBMCs from KI-069 with Nef MY9 peptide; CTL clones were then established from bulk T cells using the limiting dilution method, as described elsewhere [35] .
Intracellular Cytokine Staining Assay
C1R, B-LCL, or 721.221 cell lines prepulsed with each peptide or 721.221 cells infected with NL4-3 virus and bulk-cultured T cells or CTL clones were added to a 96-well plate, and then the cells were incubated for 2 hours at 37°C. Subsequently, brefeldin A (10 g/mL) was added, and the cells were incubated for another 4 hours. The cells were then fixed with 4% paraformaldehyde and incubated in permeabilization buffer (0.1% saponin-10% fetal bovine serum-phosphate-buffered saline [PBS]) after staining with phycoerythrin-or allophycocyanin-labeled anti-CD8 monoclonal antibody (mAb) (Dako). Thereafter, the cells were stained with fluorescein isothiocyanate-labeled antiinterferon (IFN) γ mAb (BD Bioscience). The percentage of IFN-γ-producing cells among the CD8 + T-cell population was determined by means of flow cytometry.
Chromium 51 Release Assay
The cytotoxic potential of HIV-1-specific CTL against C1R-C1202 prepulsed with appropriate peptides at various concentrations (0-10 nmol/L) was determined as described elsewhere [35] . Briefly, chromium 51-labeled target cells were plated in a 96-U plate, with or without each desired concentration of peptide. After 1 hour of incubation, CTL clones were added, and then incubation was continued for 4 hours. The supernatants were harvested and measured with a gamma counter.
Enzyme-Linked Immunospot Assay
Next, 1 × 10 5 PBMCs from HIV-1-infected individuals and peptides, at a concentration of 100 nmol/L, were added to 96-well polyvinylidene plates (Millipore) that had been precoated with 5-μg/mL anti-IFN-γ mAb; 1-D1K (Mabtech). The plates were then incubated for 16 hours at 37°C and subsequently washed with PBS before the addition of biotinylated anti-IFN-γ mAb (Mabtech) at 1 µg/mL. After the plates had been incubated at room temperature for 90 minutes, they were washed with PBS and then incubated with streptavidin-conjugated alkaline phosphatase (Mabtech) for 60 minutes at room temperature. After washes with PBS, individual cytokine-producing cells were visualized as dark spots after a 20-minute reaction with 5-bromo-4-chloro-3-indolyl phosphate and nitroblue tetrazolium in the presence of an alkaline phosphatase-conjugated substrate (Bio-Rad). The spots were counted with an Eliphoto-Counter (Minerva Teck). The mean plus 3 standard deviations for the number of spots in PBMCs from 10 HIV-1-infected antiretroviral therapy-naive HLA-B*52:01 − C*12:02 − individuals for these peptides was 56 spots/10 6 PBMCs. Therefore, we defined >100 spots/10 6 PBMCs as a positive response.
We used the Mann-Whitney test to calculate the significance of differences in data and the Spearman rank correlation test to calculate the significance of correlations in data. Differences were considered significant at P < .05.
RESULTS
Identification of 2 Novel HLA-C*12:02-Restricted HIV-1 Epitopes
Two Pol-specific HLA-C*12:02-restricted CTLs were previously identified [14] . We sought to identify other HLA-C*12:02-restricted epitopes. We first analyzed the responses of PBMCs from an HIV-1-infected donor, KI-069 (HLA-A*24:02/-, HLA-B*40:06/52:01, HLA-C*03:04/12:02), to 4 cocktails of overlapping Nef peptides, including 8 17-mer peptides. We found a positive response of bulk-cultured T cells with Nef cocktail 4, which included 8 single peptides (Nef17-25 to Nef17-33) and identified the response to 2 single peptides, Nef17-32 and Nef17-33 (Supplementary Figure S1A) . T-cell responses to these peptides were found when the bulk-cultured T cells were stimulated with B-LCLs from KI-069 and U-35 sharing HLA-B*52:01 and HLA-C*12:02 but not when those from individuals without these alleles were examined (Supplementary Figure S1B) .
Further analysis using C1R transfectant cells expressing HLA-C*12:02 demonstrated that the responses of CD8 + T cells specific for the Nef17-32 or Nef17-33 peptide were restricted by HLA-C*12:02 (Supplementary Figure S1C) and that the T cells responded to only Nef11-97 and Nef11-98 of a panel of 11-mer peptides covering Nef 17-32 and Nef17-33 peptides.
(Supplementary Figure S1D) . To determine the minimum length of the epitope, we generated truncated peptides of Nef11-97 and Nef11-98 and then tested the responses of the bulk T cells to these peptides. The results showed that the T-cell response to a 9-mer peptide Nef11-97 (MY9) was strongest of those to these peptides ( Figure 1A ), indicating that MY9 was the minimum T-cell epitope. These T cells recognized HIV-1-infected .221 cells expressing HLA-C*12:02 (.221-C1202) but We next analyzed the responses to Gag peptides. We used 11-mer overlapping Gag peptide cocktails (25 cocktails) previously generated [24] . The responses to 3 Gag cocktails (Gag4, Gag10, and Gag16) analyzed with the enzyme-linked immunospot assay were more strongly detected in HLA-C*12:02 + than in HLA-C*12:02 − individuals (Supplementary Figure  S2A) . Our previous study demonstrated that Gag10 and Gag16 cocktail peptides included CTL epitope peptides restricted by HLA-B*52:01 [24] . Therefore, we focused on the Gag4 cocktail peptide to identify HLA-C*12:02-restricted CTL epitopes.
We analyzed PBMCs from HLA-B*52:01 + C*12:02 + individual KI-848, which showed a positive response to Gag4 (Gag11-31 Figure S2B) . To determine the HLA restriction of this T-cell response, we simulated PBMCs from KI-848 with Gag11-40 and cultured them for 2 weeks. Intracellular cytokine staining (ICS) analysis using C1R-C*12:02 showed that the Gag11-40-specific T-cell response was restricted by HLA-C*12:02 (Supplementary Figure S2C) . We next generated 8 truncated peptides of Gag11-40 (YH11) and then analyzed T-cell responses to these peptides. The bulk T cells responded to 4 peptides (ie, YH11, NH10, TH9, and VH8; (Figure 2A, left) ; though the response to TH9 was stronger than to the other 3 peptides (Figure 2A, right) . TH9-specific T cells recognized HIV-1-infected .221-C1202 but not HIV-1-uninfected .221-C1202 or HIV-1-infected .221 cells ( Figure 2B ). These results indicated that TH9 was presented as an epitope in the HIV-1-infected cells. We finally investigated the frequency of HIV-1-infected individuals with TH9-specific T cells. The specific T cells were detected in only 2 of 80 individuals ( Figure 2C ), indicating that TH9 was not an immunodominant epitope. 
Effect of 2 HLA-C*12:02-Restricted T Cells on Clinical Outcome
Our group previously identified HLA-C*12:02-restricted CTLs specific for 2 Pol epitopes, IY11 and KY9 [14, 36] . IY11-specific CTLs were detected in approximately 20 % of HIV-1-infected HLA-C*12:02 + individuals [36] , whereas KY9-specific CTLs were found in only 3 of 80 HIV-1-infected HLA-C*12:02 + individuals (Supplementary Figure S3) . We therefore analyzed the effect of T cells specific for 2 immunodominant epitopes, Pol IY11 and Nef MY9, on the clinical outcome in 469 HIV-1-infected individuals. The CD4 + T-cell count was significantly higher in responders to MY9 or IY11 than that in nonresponders. On the other hand, the pVL was significantly lower in responders to IY11 than in nonresponders. Responders to MY9 showed a trend for a lower pVL than nonresponders (Table 1 ). These results suggested that these 2 HLA-C*12:02-restricted T cells may have had the ability to suppress HIV-1 replication in HIV-1-infected individuals. The results described above may reflect the effect of HLA-B*52:01-restricted CTLs on controlling HIV-1 in individuals with HLA-B*52:01-C*12:02 haplotype rather that in those with HLA-C*12:02-restricted CTLs. We therefore analyzed the effect of the responses to IY11 and MY9 on the clinical outcome in 110 individuals with the HLA-B*52:01-C*12:02 haplotype. The responders to IY11 revealed a trend for a lower pVL and a higher CD4 + cell count than in nonresponders, whereas responders to MY9 showed a significantly higher CD4 + cell count ( Figure 3A) . The breadth of these T-cell responses was inversely correlated with the pVL and positively correlated with the CD4 + cell count ( Figure 3B ). These results suggest that these HLA-C*12:02-restricted CTLs contributed to the control of HIV-1 in individuals with this haplotype. Murakoshi et al [24] previously identified 5 HLA-B*52:01-restricted CTLs controlling HIV-1 replication in vivo. Of these epitopes (MI8, QA11, RI8, WV8, and SI8), QA11 (QMLKETINEEA) and MI8 (MQMLKETI) were overlapping. QA11-and MI8-specific CTLs were detected in 11 and 44 of 100 HLA-B*52:01 + individuals, respectively [24] . The response to MI8 was higher than that to QA11 in the 11 individuals with both QA11-and MI8-specific T cells (Supplementary Figure S4A) , suggesting the cross-recognition of QA11 by MI8-specific T cells. We therefore investigated whether QA11-specific CTL clone could cross-recognize MI8. A QA11-specific CTL clone established from KI-774 recognized the MI8 peptide much more than the QA11 peptide (Supplementary Figure S4B) . These results strongly suggest that QA11 was not an epitope or only a very weak one.
Effect of the T-Cell
We further analyzed T-cell responses to 4 HLA-B*52:01-restricted epitopes (ie, MI8, RI8, WV8, and SI8) in 110 HLA-B*52:01 + C*12:02 + individuals. The response to WV8 or SI8 peptide was correlated inversely with pVL and positively with CD4 + cell count. On the other hand, the response to MI8 was correlated inversely with pVL whereas that to RI8 positively with CD4 + cell count ( Figure 4A ). The responses to WV8 and SI8 were the strongest of the responses to the 6 epitopes, though those to the other 4 epitopes were similar. Next, we investigated the total effect of these 4 HLA-B*52:01-restricted T cells and 2 HLA-C*12:02-restricted ones on clinical outcome. The breadths of these T-cell responses were correlated inversely with the pVL (r = −0.46; P = 4.3 × 10 −7 ) and positively with the CD4 + cell count (r = 0.44; P = 1.3 × 10 −6 ) ( Figure 4B ). The results indicate that these T cells had a strong ability to control HIV-1 in HIV-1-infected individuals with the HLA-B*52:01-C*12:02 haplotype.
DISCUSSION
The HLA-B*52:01-C*12:02 haplotype was previously shown to be significantly associated with better clinical outcomes in HIV-1-infected Japanese individuals [22] . This finding suggested that HLA-B*52:01-restricted and/or HLA-C*12:02-restricted CTLs may control HIV-1 in these individuals. However, it was difficult to discriminate the impact of HLA-C*12:02-restricted from HLA-B*52:01-restricted T-cell-mediated immune pressure on clinical outcomes, because the HLA-C*12:02 allele has a strong linkage with HLA-B*52:01 in the Japanese population [27, 28] . Later studies showed the contribution of HLA-B*52:01-restricted CTLs to the control of HIV-1 [24] . On the other hand, it was impossible to evaluate the impact of HLA-C*12:02-restricted T-cell-mediated immune pressure on clinical outcomes, because only 2 HLA-C*12:02-restricted Pol epitopes (KY9 and IY11) were identified [31] , despite the high frequency of the HLA-C*12:02 allele in the Japanese population.
We therefore sought to identify novel HLA-C*12:02-restricted epitopes in HIV-1-infected Japanese individuals in the present study. We identified 2 novel epitopes, Nef MY9 and Gag TH9, Abbreviations: HIV-1, human immunodeficiency virus type 1; pVL, plasma viral load.
a The significance of differences was analyzed using the Mann-Whitney test.
using different methods and then demonstrated that Nef MY9 was an immunodominant epitope. On the other hand, previous studies showed that the responders to KY9 and IY11 were detected in 2.5% and 23.8% of HLA-C*12:02 + individuals, respectively. These findings indicated that MY9 and IY11 were immunodominant epitopes in HLA-C*12:02 + Japanese individuals, and they further implied that T cells specific for these immunodominant epitopes may have contributed to HIV-1 control in these individuals. Indeed, the responders to IY11 or MY9 had a significantly lower pVL and/or higher CD4 + cell count than the nonresponders among HIV-1-infected Japanese individuals and even in HLA-B*52:01 + HLA-C*12:02 + ones. Thus, we here demonstrated that these 2 HLA-C*12:02-restricted CTLs had the ability to control HIV-1 in HLA-B*52:01 + C*12:02 + individuals. The analyses of the T-cell responses in 110 HLA-B*52:01 + C*12:02 + individuals demonstrated that HLA-B*52:01 + C*12:02 + responders to Pol IY11 showed a trend for a lower pVL and a higher CD4 + cell count than nonresponders, and HLA-B*52:01 + C*12:02 + responders to MY9 also had significantly higher CD4 + cell counts than nonresponders. The effect of these HLA-C*12:02-restricted T cells on pVL and CD4 + cell count was weaker than that of those specific for 2 HLA-B*52:01-restricted epitopes, WV8 and SI8; but it was mostly similar to that of those specific for other HLA-B*52:01-restricted ones, MI8 and RI8. We analyzed the total effect of 4 HLA-B*52:01-restricted and 2 HLA-C*12:02-restricted T cells on the clinical outcome in HLA-B*52:01 + C*12:02 + individuals. The breadths of these 6 T-cell responses showed strong inverse and positive correlations with pVL and CD4 + cell count, respectively. These results indicate that the HLA-C*12:02-restricted CTLs had a strong effect on the control of HIV-1 together with the 4 HLA-B*52:01-restricted CTLs in HIV-1-infected Japanese individuals with the HLA-B*52:01-C*12:02 haplotype.
A previous study demonstrated that the HLA-C expression level is associated negatively with pVL in European and African Americans and positively with HLA-C-restricted CTL responses Statistical analysis was performed using the Spearman rank correlation test. Differences in pVL or CD4 + cell count between nonresponders and responders to 1, 2, 3, and 4-6 epitopes were statistically analyzed using the Mann-Whitney test.
in Africans [15] . Although findings from that study strongly suggested that HIV-1-specific CTLs restricted by high-expressing HLA-C alleles effectively control HIV-1, direct evidence for the effect of HLA-C-restricted CTLs on HIV-1 control had not yet been demonstrated. In the present study, we for the first time demonstrated the contribution of HLA-C-restricted CTLs to HIV-1 control in HIV-1-infected individuals, though HLA-C*12 is expressed at a medium level among HLA-C alleles [15] . It is known that HLA-B*52:01 is associated with Takayasu arteritis [37] [38] [39] [40] [41] [42] and ulcerative colitis [38, 40, 43] and that HLA-C*12:02 is associated with late-onset psoriasis in Japanese individuals [44] . Because the HLA-C*12:02 allele has a very strong linkage with the HLA-B*52:01 allele in the Japanese population, it is likely that this haplotype is associated with this disease. Indeed, 1 group demonstrated that this haplotype is also associated with ulcerative colitis [45] . Thus, HLA-B*52:01-C*12:02 is a protective allele in HIV-1 infection and is also associated with these autoimmune diseases. Similar correlation between autoimmune diseases or drug hypersensitivity and HIV-1 infection is well known for HLA-B*27 and HLA-B*57, which are protective alleles in HIV-1 infection [46] . HLA-B*27 is associated with autoimmune diseases such as ankylosing spondylitis [47, 48] , and HLA-B*57 is associated with drug hypersensitivity [49, 50] . The immune responses elicited by these HLA molecules thus may not only control HIV-1 but also, when strong, may cause autoimmune diseases or allergy.
The present study provided new findings that HIV-1 is controlled by HLA-C*12:02-restricted CTLs together with HLA-B*52:01-restricted CTLs in Japanese individuals with the protective HLA-B*52:01-C*12:02 haplotype. Because HLA-C*12:02 plays an important role together with KIR2DL2 in NK cell-mediated control of HIV-1 [26] , this HLA-C allele provides immune pressure on HIV-1via both CTLs and NK cells. Taken together with HLA-B*52:01-restricted CTLs, this HLA-C haplotype elicits strong immune responses against HIV-1. This HLA-B*52:01-C*12:02 haplotype may provide strong immune responses to many antigens, resulting in autoimmune diseases, such as Takayasu arteritis, psoriasis, and ulcerative colitis.
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